MET expression

FAXDC2 acts as a tumor suppressor in HCC, and its knockdown promotes cell proliferation, migration, invasion, and EMT via upregulating c-Met expression and enhancing its phosphorylation in HepG2 cells. Therefore, the FAXDC2/c-Met axis may serve as a noval potential therapeutic target for HCC intervention.

P1, N=18, Not yet recruiting, Peking Union Medical College Hospital

In preclinical studies, B6ADC exhibits potent cytotoxicity in vitro across various TROP2/c-Met-expressing cancer cell lines and superior tumor inhibition in vivo compared with single-target ADC combination, including the clinically approved TROP2 ADC sacituzumab govitecan and c-Met ADC Teliso-V, as well as their combination. Notably, B6ADC eradicates giant tumors with a single dose at a low concentration of 2.2 mg/kg. We present a nanobody-based BsADC that simultaneously targets TROP2 and c-Met, with broad-spectrum antitumor activity, and improves selectivity for tumors with dual-positive or weakly positive antigen expression, offering a promising strategy for treating pancreatic cancer and other TROP2/c-Met-expressing malignancies.

P1/2, N=140, Recruiting, Chong Kun Dang Pharmaceutical | Not yet recruiting --> Recruiting

Therapeutic target proteins in SCLC exhibit dynamic changes, emphasizing the need for biomarker-driven strategies. Rebiopsy may guide therapeutic decisions, and further research is needed to optimize patient selection for ADCs and BiAbs.

The proportion of the patients benefitting of the treatment and its safety profile justify larger, controlled studies to further investigate the added role of combining cabozantinib with metronomic temozolomide. ClinicalTrials.gov identifier: NCT04893785.

Using the IsoTar target prediction tool, we identified STAT3 as a key regulator and confirmed STAT3 protein downregulation upon transfection with miR-411ed. We further investigated the effect of miR-411ed in vivo, observing a reduction in tumor size with miR-411ed in combination with Osimertinib but not with miR-411ed or Osimertinib treatment alone, confirming the effectiveness of miR-411ed in TKI response.

Additionally, at 60 min postinjection, it showed satisfactory radioactive uptake in lung cancer (tumor-to-lung ratio [TLR]: 4.87 [range, 3.12-7.55]), which positively correlated with c-Met expression (R = 0.71, P = 0.034). Overall, [68Ga]Ga-NOTA-PEG2-Glc-MetP shows favorable pharmacokinetics and a strong correlation with c-Met expression, supporting its potential as a promising PET imaging agent.

Temab-A monotherapy demonstrated antitumor activity and a manageable safety profile in patients with advanced GEA. The findings support further clinical development of Temab-A, particularly in combination with other agents to improve outcomes for patients with 2L+ GEA.

ZM fusion was associated with a worse prognosis in both astrocytoma (OS p < 0.001, PFS p < 0.001) and glioblastoma (OS, p = 0.252; PFS, p = 0.010) patients. We highlight the utmost relevance of ZM fusion as an adverse prognostic factor in astrocytoma (11/382, 2.88%) and glioblastoma grade 4 (11/401, 2.74%) patients and suggest that the grading of these tumors should be refined.

This study provides the first direct evidence from ex vivo fresh TIL assays using human NSCLC clinical specimens that amivantamab can activate immune responses. EGFR and MET expression may serve as potential biomarkers for amivantamab-induced immune responses.

EMT was induced by transfecting HCC827 lung cancer cells with the Snail gene, followed by MET induction via dexamethasone...Furthermore, P-gp membrane expression increased synergistically with the continuous induction of EMT/MET. This study demonstrated that P-gp expression and activity increase at both the EMT and MET stages in cancer metastasis, suggesting that different mechanisms may be involved at each stage.